Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Common Equity (2016 - 2025)

Historic Common Equity for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $374.1 million.

  • CorMedix's Common Equity rose 53722.53% to $374.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $374.1 million, marking a year-over-year increase of 53722.53%. This contributed to the annual value of $84.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that CorMedix reported Common Equity of $374.1 million as of Q3 2025, which was up 53722.53% from $220.6 million recorded in Q2 2025.
  • CorMedix's Common Equity's 5-year high stood at $374.1 million during Q3 2025, with a 5-year trough of $46.2 million in Q2 2024.
  • For the 5-year period, CorMedix's Common Equity averaged around $92.5 million, with its median value being $62.3 million (2021).
  • Per our database at Business Quant, CorMedix's Common Equity plummeted by 2943.39% in 2024 and then soared by 53722.53% in 2025.
  • CorMedix's Common Equity (Quarter) stood at $62.8 million in 2021, then dropped by 12.32% to $55.1 million in 2022, then surged by 51.11% to $83.2 million in 2023, then increased by 1.75% to $84.7 million in 2024, then surged by 341.94% to $374.1 million in 2025.
  • Its Common Equity stands at $374.1 million for Q3 2025, versus $220.6 million for Q2 2025 and $114.9 million for Q1 2025.